Can shrinking tumors before surgery improve robotic lung cancer outcomes?
NCT ID NCT07528066
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study enrolls 200 people with stage IIB-III non-small cell lung cancer who receive chemo-immunotherapy before robotic surgery. Researchers want to see if tumor and lymph node shrinkage (downstaging) leads to better surgical results, like complete tumor removal and fewer complications. Participants are followed from multiple international centers to collect data on surgery and recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors predict which lung cancer patients will have the best surgical outcomes after chemo-immunotherapy.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients or change current practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT CHEMOIMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliera di Cosenza
RECRUITINGCosenza, 87100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Saint Joseph Marseille
RECRUITINGMarseille, 13001, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jiangsu Cancer Institute & Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Chest Hospital, Shanghai Jiao Tong University Medicine of School
RECRUITINGShanghai, 200030, China
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shenzhen People's Hospital
RECRUITINGShenzhen, Guangdong, 518020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjing, Tianjing, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital, Rouen
RECRUITINGRouen, 76000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact